A Phase 2 interventional study of rebamipide 2% ophthalmic suspension and placebo eye drops in Dry Eye Syndromes and Keratoconjunctivitis Sicca, sponsored by Kubota Vision Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-11.
Sponsored by Kubota Vision Inc. · Phase 2, Interventional, and Treatment
The purpose of this study is to evaluate the safety and efficacy of rebamipide 2% suspension for the treatment of patients with dry-eye.
1,292 studies on the registry are indexed under Dry Eye Syndromes; 191 are open to participants now.
This study's enrollment of 220 is above the median of 60 across 1,077 interventional studies indexed under Dry Eye Syndromes.
Browse Dry Eye Syndromes studies →Kubota Vision Inc. is the lead sponsor of 21 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: rebamipide 2% ophthalmic suspension
Drug: placebo eye drops
Instill one drop in each eye four times daily for 12 weeks.
Instill one drop in each eye four times daily for 12 weeks.
Total fluorescein corneal staining score
Time frame: 4 weeks
Primary ocular discomfort
Time frame: 4 weeks
Dry eye symptoms
Time frame: 12 weeks
Ocular staining
Time frame: 12 weeks
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kubota Vision Inc.